Skip to content
Safety ProfileEvidence-Based

CJC-1295 Side Effects

Honest, evidence-based safety analysis for CJC-1295. Frequency data, severity classification, data limitations, and what we genuinely don't know.

Quick Answer

CJC-1295's most commonly reported side effects are facial flushing and warmth shortly after injection, headache, and water retention — all related to acute GH elevation. These effects are typically mild and transient. The side-effect profile is generally more manageable than direct GH administration, though long-term human data is limited.

→ CJC-1295 Dosage→ CJC-1295 Benefits→ Full CJC-1295 Profile
Table of Contents

Data Context: What We Actually Know

Important: data limitations

Human safety data for CJC-1295 is limited to short-term pharmacokinetic studies and community self-reports. Long-term use data in humans does not exist. GH-related risks (e.g., insulin resistance, potential cancer associations) are extrapolated from GH research, not directly confirmed for CJC-1295.

Side Effects by Severity

MildModerateSevere / Serious
Facial flushing and warmth after injectionMild

Frequency: Common — reported by 30–50% of users anecdotally

Mediated by acute GH release and vasodilatory effects. Typically lasts 10–30 minutes post-injection. Normal and not harmful.

HeadacheMild

Frequency: Common — 20–35% anecdotally

Usually transient, within 1–2 hours of injection. Often resolves with adequate hydration.

Water retention and mild bloatingMild

Frequency: Common during first weeks — 30–40% anecdotally

GH causes sodium and water retention early in use. Typically diminishes after 2–4 weeks as the body adapts.

Numbness or tingling in extremities (paresthesia)Mild

Frequency: Uncommon — 10–15% anecdotally

Associated with GH-mediated fluid shifts and carpal tunnel-like effects. Usually resolves with dose reduction.

Injection site reaction (redness, minor swelling)Mild

Frequency: Common with subcutaneous injection

Standard subcutaneous injection reaction. Rotate sites.

Potential insulin resistance with long-term useModerate

Frequency: Theoretical risk — no direct confirmation in CJC-1295 studies

Elevated GH is known to cause insulin resistance. Whether CJC-1295's GH elevation is sustained enough to impair glucose metabolism is unknown but warrants monitoring with extended use.

Contraindications

  • ✕Active cancer or history of GH-sensitive malignancies (elevated GH/IGF-1 may promote growth)
  • ✕Diabetes or significant insulin resistance (GH elevation may worsen glycemic control)
  • ✕Pregnancy and breastfeeding
  • ✕Pediatric use (open epiphyses risk with elevated GH)
  • ✕Active acromegaly or gigantism

Drug Interactions

No formal pharmacokinetic drug interaction studies have been conducted for most research peptides. The interactions below are theoretical, mechanism-based, or derived from limited case reports.
  • ⚠Insulin and diabetes medications: GH elevation increases insulin resistance — may require dose adjustment of diabetes medications
  • ⚠Glucocorticoids (prednisone, etc.): may blunt GH response to GHRH stimulation
  • ⚠Thyroid hormone: GH increases conversion of T4 to T3 — relevant for those on thyroid medications
  • ⚠Exogenous GH (somatropin): additive effects — risk of GH excess symptoms (acromegalic features) with combined use

Frequently Asked Questions

What are the side effects of CJC-1295?
The most commonly reported: facial flushing and warmth after injection (very common, related to acute GH release), headache, water retention and bloating (especially in early weeks), and occasionally tingling or numbness in hands or feet. These are generally mild and diminish with continued use or dose adjustment. Serious adverse effects have not been documented in short-term studies.
Does CJC-1295 cause insulin resistance?
Elevated GH is known to cause insulin resistance — this is a well-established pharmacological effect of GH. Whether the degree of GH elevation caused by CJC-1295 (which maintains pulsatile, physiological-range GH) is sufficient to meaningfully impair insulin sensitivity is unknown. This risk is lower than with direct exogenous HGH but cannot be dismissed. Monitoring fasting glucose and HbA1c with extended use is reasonable.
Why do I feel flushed after injecting CJC-1295?
The flush is a direct consequence of the acute GH pulse triggered by the injection. Growth hormone has vasodilatory effects mediated by nitric oxide. The sensation of warmth or flushing shortly after injection is a reliable sign that the peptide is working — GH is being released. This effect is normal, typically lasts 15–30 minutes, and diminishes as the body adapts.
Can CJC-1295 cause acromegaly?
Acromegaly results from chronically supraphysiological GH levels (typically from a pituitary tumor or excessive GH injection). CJC-1295 stimulates the pituitary to release GH — it cannot produce GH levels beyond what the pituitary is capable of generating naturally. With physiological doses, GH levels remain within (or slightly above) the normal range. The risk of acromegalic features from CJC-1295 at standard doses is considered very low, though not impossible with extremely high doses or concurrent exogenous GH.
Is CJC-1295 safer than HGH?
CJC-1295 is generally considered to have a more favorable safety profile than direct exogenous HGH because: (1) it works through the pituitary's natural feedback system, preventing supraphysiological GH levels; (2) it preserves pulsatile GH secretion patterns; (3) it does not suppress natural GH production (unlike exogenous HGH). However, it lacks the long-term safety data that exogenous HGH has accumulated through decades of clinical use.

References

  1. 1
    A single dose of the long acting GH secretagogue CJC-1295 stimulates GH secretion for days in normal young adults(2006)PubMed ↗
  2. 2
    Growth hormone-releasing hormone: clinical studies and therapeutic aspects(1998)PubMed ↗
  3. 3
    Pharmacokinetics and pharmacodynamics of GRF analogs in rhesus macaques(2003)PubMed ↗

Last updated: 2026-02-26